NeoStem Appoints Stephen W. Potter as Executive Vice President

NeoStem Appoints Stephen W. Potter as Executive Vice President

NEW YORK, July 22, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS)
("NeoStem" or the "Company"), a leader in the emerging cellular therapy
market, announced today the appointment of Stephen W. Potter as Executive Vice
President of the Company. Mr. Potter is a seasoned and successful senior
executive with extensive management experience in the biotechnology and
pharmaceutical industries. Stephen has served since February on NeoStem's
Board of Directors and its Nominating and Governance Committee. Upon his
appointment as Executive Vice President, Stephen resigned from the Company's
Board of Directors.

Stephen Potter
 NeoStem Appoints Stephen
 W. Potter as Executive
 Vice President.

"Stephen brings a history of success in cell therapy development and global
operations and, combined with his existing working knowledge of both the
research and operations of our Company, he will be a key figure in our future
success," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "As NeoStem
moves forward in growing its contract development and manufacturing services
business, continues the development and looks ahead to the commercial launch
of its therapeutic product pipeline, and evaluates multiple business
development opportunities, we expect Stephen's demonstrated experience to have
a significant impact on our Company's value."

"I am excited to join the NeoStem team, working collaboratively with its
management and advisors, to drive significant value for the Company," said Mr.
Potter."I believe that cell therapies will play a significant role in the
fight against chronic disease.NeoStem has developed a unique platform of
contract services as well as developing its own pipeline of cell therapy
products and I am pleased to work with Dr. Robin Smith and the Company's top
notch teamin the building of a world class, highly competitive and profitable

Most recently, Mr. Potter served as Senior Vice President of Operations and
Corporate Development for Osiris Therapeutics, Inc. where he worked as a
member of the senior leadership that achieved approval of the first-ever stem
cell drug therapy, Prochymal®. He was also responsible for the launch and
overall management of the Bio-Surgery business unit and had operational
oversight for multiple functional areas including manufacturing, human
resources, IT, legal, and business development.Prior to his tenure at Osiris,
Mr. Potter served as Senior Vice President of Corporate and Business
Development at Genzyme Corporation. Over his ten years at Genzyme, he was the
senior leader for its global corporate and business development team that
provided strategic and transaction support, including support for many of
Genyzme's cell therapy opportunities. Mr. Potter has also held positions at
DuPont Pharmaceuticals, E.I. Dupont de Nemours and Company, Inc., and Booz
Allen & Hamilton. He earned a B.S. from University of Massachusetts and an MBA
from Harvard Business School.

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our
business model includes the development of novel proprietary cell therapy
product, as well as operating a contract development and manufacturing
organization that provides services to others in the regenerative medicine
industry. The combination of a therapeutic development business and
revenue-generating service provider business provides the Company with
capabilities for cost effective in-house product development and immediate
revenue and cash flow generation.

For more information, please visit:

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the successful execution
of the Company's business strategy, including with respect to the Company's
research and development and clinical evaluation efforts as well as efforts
towards development of cellular therapies, including with respect to AMR-001,
the future of the regenerative medicine industry and the role of stem cells
and cellular therapy in that industry and the Company's ability to
successfully grow its contract development and manufacturing business. The
Company's actual results could differ materially from those anticipated in
these forward- looking statements as a result of various factors. Factors that
could cause future results to materially differ from the recent results or
those projected in forward-looking statements include the "Risk Factors"
described in the Company's Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 11, 2013 and in the Company's
periodic filings with the SEC. The Company's further development is highly
dependent on future medical and research developments and market acceptance,
which is outside its control.

A photo accompanying this release is available at

The photo is also available via AP PhotoExpress.

         Dr. Robin L. Smith
         Chairman and CEO
         Phone: +1-212-584-4174

NeoStem Inc. Logo
Press spacebar to pause and continue. Press esc to stop.